Erlotinib
- PDF / 141,528 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 20 Downloads / 178 Views
1
Erlotinib Alopecia, follicular skin eruption and pruritus in an elderly patient: case report A woman [aged not clearly stated] developed alopecia, a follicular skin eruption and pruritus during treatment with erlotinib for non-small cell lung cancer (NSCLC). The woman, who was diagnosed with NSCLC at age 74 years, received gefitinib for more than 40 months, but developed a follicular skin eruption. She then received an experimental epidermal growth factor receptor tyrosine kinase inhibitor briefly without developing a skin-related toxicity. She subsequently started receiving erlotinib 150 mg/day. Within 1 week, a grade 2 follicular skin eruption involving her face and scalp developed with severe pruritus of lesions and other areas. The woman received topical corticosteroids and antibacterials to her facial area, and she also received oral tetracycline and hydroxyzine. Within 2 weeks, her skin eruption and pruritus improved. Six weeks after erlotinib initiation, she noticed hair thinning and loss from her scalp. Most of her scalp hair had fallen out by 16 weeks of erlotinib treatment; some regions in a halo-pattern around her former scalp hair were spared. The remaining hair on her scalp appeared more wavy than it previously was. She had new growth of scalp hair in the affected area. At the most recent follow-up, 20 weeks after erlotinib initiation, she had slow growth of scalp hair. Author comment: "The findings of hair changes after [epidermal growth factor receptor] inhibition are consistent with experimental evidence that [epidermal growth factor receptor] plays a crucial role in the regulation of the hair growth cycle." Costa DB, et al. Erlotinib-associated alopecia in a lung cancer patient. Journal of 801098615 Thoracic Oncology 2: 1136-1138, No. 12, Dec 2007 - USA
0114-9954/10/1185-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 19 Jan 2008 No. 1185
Data Loading...
